Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:KYMR NASDAQ:MOR NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$17.29+2.4%$15.41$12.72▼$34.47$2.89B0.631.22 million shs1.47 million shsKYMRKymera Therapeutics$45.18+4.0%$39.08$19.45▼$53.27$2.83B2.18626,814 shs1.01 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVIRVir Biotechnology$5.93+11.9%$5.17$4.32▼$14.45$732.66M1.221.36 million shs2.60 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+2.86%+4.58%+0.72%+13.36%-38.92%KYMRKymera Therapeutics-0.87%-2.27%-8.80%+81.34%+35.89%MORMorphoSys0.00%0.00%0.00%0.00%+1.66%VIRVir Biotechnology+0.57%+3.72%-2.75%-7.34%-37.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMVTImmunovant1.3923 of 5 stars3.52.00.00.00.01.70.0KYMRKymera Therapeutics3.1439 of 5 stars4.51.00.00.03.02.50.0MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.9982 of 5 stars3.42.00.00.01.43.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.90Moderate Buy$38.33121.71% UpsideKYMRKymera Therapeutics 3.00Buy$59.1130.83% UpsideMORMorphoSys 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$32.86454.08% UpsideCurrent Analyst Ratings BreakdownLatest VIR, MOR, KYMR, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKYMRKymera Therapeutics$47.07M62.51N/AN/A$12.90 per share3.50MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17VIRVir Biotechnology$74.21M11.05N/AN/A$8.35 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$413.84M-$2.740.00N/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.100.00N/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AVIRVir Biotechnology-$521.96M-$4.220.00N/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)Latest VIR, MOR, KYMR, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025KYMRKymera Therapeutics-$0.84N/AN/AN/A$17.37 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A11.1611.16KYMRKymera TherapeuticsN/A8.498.49MORMorphoSys4.981.381.38VIRVir BiotechnologyN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%KYMRKymera TherapeuticsN/AMORMorphoSys18.38%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant5.90%KYMRKymera Therapeutics16.01%MORMorphoSys0.05%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120170.92 million160.84 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableVIRVir Biotechnology580138.24 million116.12 millionOptionableVIR, MOR, KYMR, and IMVT HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?July 9 at 3:39 PM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 7 at 2:14 AM | marketbeat.comVicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJuly 3, 2025 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of StockJuly 2, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of RevenueJune 30, 2025 | marketbeat.comIs Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?June 25, 2025 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 12, 2025 | marketbeat.comJanet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJune 3, 2025 | insidertrades.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.comGilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programsMay 22, 2025 | fiercebiotech.comFVir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)May 22, 2025 | benzinga.comVir’s hepatitis B combo falls short in Phase II trialMay 12, 2025 | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12, 2025 | businesswire.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comWhy Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%May 10, 2025 | aaii.comAQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir's 'functional cure' candidate for hepatitis B misses mark in phase 2May 10, 2025 | fiercebiotech.comFVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?3 Stocks Set to Double—And There's Still Time to BuyBy Nathan Reiff | June 12, 2025View 3 Stocks Set to Double—And There's Still Time to BuyMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for Outperformance3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadVIR, MOR, KYMR, and IMVT Company DescriptionsImmunovant NASDAQ:IMVT$17.29 +0.40 (+2.37%) Closing price 04:00 PM EasternExtended Trading$17.82 +0.53 (+3.04%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$45.18 +1.75 (+4.03%) Closing price 04:00 PM EasternExtended Trading$44.91 -0.27 (-0.60%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/8/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Vir Biotechnology NASDAQ:VIR$5.93 +0.63 (+11.89%) Closing price 04:00 PM EasternExtended Trading$5.95 +0.02 (+0.34%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
